Madrigal Pharmaceuticals, Inc.
MDGL
$291.82
$8.963.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.26% | 44.45% | 29.62% | -3.00% | -31.51% |
| Total Depreciation and Amortization | 19.83% | 21.81% | 11.61% | 58.93% | 18.31% |
| Total Amortization of Deferred Charges | -9.54% | 0.42% | 1.69% | -27.94% | -13.01% |
| Total Other Non-Cash Items | 18.03% | 1.69% | -28.54% | 22.62% | 34.00% |
| Change in Net Operating Assets | 41.15% | -392.48% | 368.10% | 63.67% | -235.29% |
| Cash from Operations | 14.93% | -55.99% | 50.36% | 9.53% | -86.60% |
| Capital Expenditure | -- | 74.97% | -494.66% | 63.31% | 65.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 443.16% | 76.31% | -65.30% | -223.94% | 127.25% |
| Cash from Investing | 441.77% | 76.31% | -65.76% | -224.52% | 127.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -56.30% | 164.96% | -94.44% | -76.62% | 19.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -56.30% | 164.96% | -94.44% | -76.62% | 19.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 163.04% | 49.35% | -113.08% | -123.52% | 1,280.35% |